临床实践指南:慢性鼻窦炎的手术治疗
该指南由美国耳鼻咽喉头颈外科学会基金会制定,针对成人慢性鼻窦炎的手术管理提出关键行动声明,包括术前诊断核实、手术指征评估、避免无指征抗菌治疗、术前CT规划、术后随访等,其中3项为强推荐,9项为推荐,无选项级推荐。
要点
- 术前应核实慢性鼻窦炎诊断符合指南标准,并基于症状、疾病特征、生活质量和既往治疗评估手术指征(强推荐)。
- 无显著或持续脓性鼻漏时不应处方抗菌治疗(强推荐);不应将固定疗程药物作为手术前提(推荐)。
- 伴息肉、骨侵蚀、嗜酸性黏蛋白或真菌球的亚型最可能从手术获益;术后3–12个月应常规随访评估结局。
核心结论
- 指南为成人慢性鼻窦炎的手术管理提供循证推荐,强调术前诊断核实、个体化手术指征评估、避免无指征抗菌治疗及术后长期管理。
研究设计与样本
- 指南依据美国耳鼻咽喉头颈外科学会基金会临床实践指南制定手册(第3版)55页方案制定,专家组包括耳鼻咽喉科医师、鼻科医师、高级实践护士和医师助理及消费者代表。
主要发现
- 指南发展组做出3项强推荐(KAS 1A、1B、3)和9项推荐(KAS 2、4、5、6、7、8、9、10、11),无选项级推荐。
关键数值与推荐
- 强推荐:术前核实慢性鼻窦炎诊断符合临床实践指南的诊断标准(体征和症状),并基于症状、疾病特征、生活质量和既往药物或手术治疗评估手术指征(KAS 1A、1B)。
- 强推荐:无显著或持续脓性鼻漏(前、后或两者兼有)时,不应处方抗菌治疗(KAS 3)。
- 推荐:不应将预设的、一刀切的药物(如抗生素、类固醇、抗组胺药)方案或疗程作为成人慢性鼻窦炎手术的前提(KAS 2)。
- 推荐:应识别最可能从手术获益且最不可能从继续单独药物治疗获益的慢性鼻窦炎患者,如伴息肉、息肉伴骨侵蚀、嗜酸性黏蛋白或真菌球的亚型(KAS 4)。
- 推荐:术前应告知患者现实期望,包括慢性化或复发可能及长期药物管理的可能性,并考虑其慢性鼻窦炎亚型(KAS 5)。
临床怎么用
- 当预期获益超过单独非手术治疗、预期结局明确且患者理解术后长期疾病管理期望时,应为成人慢性鼻窦炎患者提供手术(KAS 6,推荐)。
- 若尚无,应获取细层CT扫描以检查鼻窦用于手术规划(KAS 7,推荐);不应仅基于黏膜增厚、窦腔浑浊或流出道阻塞的任意最小阈值标准规划手术范围(KAS 8,推荐)。
- 应教育计划手术的患者关于术后护理,包括疼痛控制、清创、药物管理、活动限制、重返工作、随访频率和持续时间及复发或修正手术可能(KAS 9,推荐)。
- 当鼻窦涉及息肉、骨炎、骨侵蚀或真菌病时,手术应包括窦腔(管腔)完全暴露和病变组织切除,而非仅球囊或手动窦口扩张,或转诊至能执行该范围手术的医师(KAS 10,推荐)。
- 术后3至12个月应常规随访,通过病史(症状缓解、生活质量、并发症、治疗依从性、急救药物需求及持续护理)和鼻内镜评估并记录手术结局(KAS 11,推荐)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this specialty-specific clinical practice guideline is to identify quality improvement opportunities and provide clinicians with trustworthy, evidence-based recommendations for the surgical management of chronic rhinosinusitis in adults. The target audience includes otolaryngologist-head and neck surgeons who manage adults with chronic rhinosinusitis, including candidacy and performance of endoscopic sinus surgery. METHODS: This guideline was developed using the 55-page protocol published as the American Academy of Otolaryngology-Head and Neck Surgery Foundation's Clinical Practice Guideline Development Manual (3rd edition), which summarizes the methodology for assessments of current data, topic prioritization, development of key action statements (KASs), application of value judgments, and related procedures. The guideline group represented otolaryngologists, rhinologists, advanced practice nursing and physician assistants, and consumers who represented participating national professional organizations. ACTION STATEMENTS: The Guideline Development Group made strong recommendations for the following KASs: Before considering surgery, the surgeon should verify an existing diagnosis of chronic rhinosinusitis to ensure established diagnostic criteria (signs and symptoms) from clinical practice guidelines are met, and the surgeon should assess candidacy for sinus surgery based on symptoms, disease characteristics, quality of life, and prior medical or surgical therapy (KASs 1A and 1B). The surgeon or their designee should not prescribe antibacterial therapy to an adult with chronic rhinosinusitis if significant or persistent purulent nasal discharge (anterior, posterior, or both) is absent on examination (KAS 3). The Guideline Development Group made recommendations for the following KASs: The surgeon should not endorse or require a predefined, one-size-fits-all regimen or duration of medical therapy (eg, antibiotics, steroids, antihistamines) as a prerequisite to sinus surgery for an adult with chronic rhinosinusitis (KAS 2). The surgeon should identify patients with chronic rhinosinusitis that would benefit most from surgery and are least likely to benefit from continued medical therapy alone, such as those with chronic rhinosinusitis subtypes that include, but are not limited to, chronic rhinosinusitis with polyps, polyps with bony erosion, eosinophilic mucin, or fungal balls (KAS 4). The surgeon or their designee should counsel patients before sinus surgery to establish realistic expectations, including the potential for chronicity or relapse, and the likelihood of long-term medical management, taking into account their chronic rhinosinusitis subtype (KAS 5). The surgeon should offer sinus surgery to an adult with chronic rhinosinusitis when the anticipated benefits exceed that of nonsurgical management alone, there is clarity regarding the anticipated outcomes, and the patient understands the expectation for long-term disease management following surgery (KAS 6). For an adult who is a candidate for sinus surgery, the surgeon or their designee should obtain a computed tomography (CT) scan with a fine-cut protocol, if not already available, to examine the paranasal sinuses for surgical planning (KAS 7). The surgeon should not plan the extent of sinus surgery (eg, which specific sinuses to operate on) solely based on arbitrary criteria regarding a minimal level of mucosal thickening, sinus opacification, or outflow obstruction on a CT scan (KAS 8). The surgeon or their designee should educate an adult with chronic rhinosinusitis who is scheduled for sinus surgery regarding anticipated postoperative care, specifically pain control, debridement, medical management, activity restrictions, return to work, duration and frequency of follow-up visits, and the potential for recurrent disease or revision surgery (KAS 9). When the sinus involves polyps, osteitis, bony erosion, or fungal disease in an adult with chronic rhinosinusitis who is scheduled for sinus surgery, the surgeon should perform sinus surgery that includes full exposure of the sinus cavity (lumen) and removal of diseased tissue, not just balloon or manual ostial dilation, or refer the patient to a surgeon who can perform this extent of surgery (KAS 10). The surgeon or their designee should routinely follow up to assess and document outcomes of sinus surgery for chronic rhinosinusitis, between 3 and 12 months after the procedure, through history (symptom relief, quality of life, complications, adherence to therapy, need for rescue medications, and ongoing care) and nasal endoscopy (KAS 11). There were no recommendations that were considered options from the Guideline Development Group.
引用
- Shin JJ, Wilson M, McKenna M, et al. Clinical Practice Guideline: Surgical Management of Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2025. PMID: 40424072. doi:10.1002/ohn.1287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。